Patents by Inventor Fred Harbinski

Fred Harbinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods, compositions and components for CRISPR-Cas9 editing of TGFBR2 in T cells for immunotherapy
    Patent number: 12698489
    Abstract: CRISPR/CAS-related genome editing systems, compositions and methods for targeting the TGFBR2 locus, as well as cells edited using these systems, compositions and methods are provided.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: August 4, 2026
    Assignees: EDITAS MEDICINE, INC., JUNO THERAPEUTICS, INC.
    Inventors: Stephen Michael Burleigh, Melissa Chin, Fred Harbinski, Christopher Heath Nye, Blythe D. Sather, Queenie Vong, Gordon Grant Welstead, Chris Wilson
  • METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF CBLB IN T CELLS FOR IMMUNOTHERAPY
    Publication number: 20260002159
    Abstract: CRISPR/CAS-related genome editing systems, compositions and methods for targeting the CBLB locus, as well as cells edited using these systems, compositions and methods are provided.
    Type: Application
    Filed: April 7, 2025
    Publication date: January 1, 2026
    Inventors: Andreia S. COSTA, Jason David FONTENOT, Fred HARBINSKI, Gordon Grant WELSTEAD, Chris WILSON
  • METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF CBLB IN T CELLS FOR IMMUNOTHERAPY
    Publication number: 20230137729
    Abstract: CRISPR/CAS-related genome editing systems, compositions and methods for targeting the CBLB locus, as well as cells edited using these systems, compositions and methods are provided.
    Type: Application
    Filed: November 5, 2018
    Publication date: May 4, 2023
    Inventors: Andreia S. COSTA, Jason David FONTENOT, Fred HARBINSKI, Gordon Grant WELSTEAD, Chris WILSON
  • METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF TGFBR2 IN T CELLS FOR IMMUNOTHERAPY
    Publication number: 20230061455
    Abstract: CRISPR/CAS-related genome editing systems, compositions and methods for targeting the TGFBR2 locus, as well as cells edited using these systems, compositions and methods are provided.
    Type: Application
    Filed: November 1, 2018
    Publication date: March 2, 2023
    Inventors: Stephen Michael BURLEIGH, Melissa CHIN, Fred HARBINSKI, Christopher Heath NYE, Blythe D. SATHER, Queenie VONG, Gordon Grant WELSTEAD, Chris WILSON
  • CELLS EXPRESSING A RECOMBINANT RECEPTOR FROM A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS
    Publication number: 20220184131
    Abstract: Provided herein are engineered immune cells, e.g. T cells, expressing a recombinant receptor, that contain a modified transforming growth factor-beta receptor type-2 (TGFBR2) locus encoding the recombinant receptor or a portion thereof. In some aspects, the cells are engineered by targeted integration of a transgene sequence encoding the recombinant receptor or a portion thereof, at a TGFBR2 genomic locus. Also provided are cell compositions containing the engineered immune cells, nucleic acids for engineering cells, and methods, kits and articles of manufacture for producing the engineered cells, such as by targeting a transgene sequence encoding a recombinant receptor or a portion thereof for integration into a region of a TGFBR2 genomic locus. In some embodiments, the engineered cells, e.g. T cells, can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.
    Type: Application
    Filed: April 30, 2020
    Publication date: June 16, 2022
    Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.
    Inventors: Stephen Michael Burleigh, Cedric CLEYRAT, Melissa CHIN, Fred HARBINSKI, Christopher Heath NYE, Blythe D. SATHER, Queenie VONG, G. GRANT WELSTEAD, Christopher WILSON
  • Tyrosine Kinase Inhibitor Combinations and their Use
    Publication number: 20150051210
    Abstract: The invention relates to pharmaceutical combination product comprising (i) a MET inhibitor and (ii) an FGFR inhibitor, or a pharmaceutical acceptable salt thereof, respectively, or a prodrug thereof, respectively, and at least one pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 1, 2013
    Publication date: February 19, 2015
    Applicant: Novartis AG
    Inventors: Ralph Tiedt, Alan Buckler, Fred Harbinski, Sneha Sanghavi, Douglas Jeffery, Christopher Wilson